• One of the most active HSCT HSCT: Hematopoietic Stem Cell Transplantation centers in the world.
• Best outcomes in haploidenticaTl & matched unrelated donor HSCT in the world.
• Best outcome of salvaged HSCT in leukemia.
• Performed the most unrelated PBSCT PBSCT: Peripheral blood Stem Cell Transplantation from CMDP CMDP: China Marrow Donor Program since 2014.
Total Number of HSCT (2003~2018)
As one of the most active HSCT centers, our HSCT department performs 1/10 of the total transplant cases in China every year. From 2003 to 2018, the HSCT cases totaled 5,071.
Number of HSCT (2012~2018)
Number & Type of HSCT in 2018
In 2018, we completed 773 HSCT cases, including 546 haplo haplo: Haploidentical, which means HLA mismatched related -HSCT (70.5%), 100 sibling-HSCT (12.9%), 111 unrelated matched-HSCT (14.4%) , and 12 unrelated cord blood-HSCT (1.5%), 4 auto auto: autologous-HSCT cases (0.5%).
Types of diseases by HSCT in 2018
The transplantation department is the key department of our hospital, the diseases could be treated by transplant include but not limited to the above diseases.
HCT performed with related HLA-mismatched donors is a feasible approach with acceptable outcomes, it can achieve comparable outcomes with HLA-identical sibling transplantation.
Haplo-HSCT VS. Sibling-HSCT
The cumulative incidences of II-IV aGVHD aGVHD: acute graft-versus-host disease in the matched group was 32%, and in the mismatched group was 40%.
The incidence of cGVHD cGVHD: chronic graft-versus-host disease did not differ significantly between the two groups.
Two years adjusted LFS LFS: leukemia-free survival and OS OS:overall survival in the matched group were 71% and 72%, and in the mismatched group were 64% and 71%, respectively.
The LFS and OS did not differ significantly between the two groups.
Haplo-HSCT in AML
LFS of HSCT in AML AML:Acute myeloid leukemia were 76.9% at CR1 CR1:the first complete remission , 74.1% at CR2 CR2:the second complete remission and 48.2% at NR NR:no remission respectively.
Haplo-HSCT in ALL
LFS of HSCT in ALL ALL:Acute lymphoblastic leukemia
are 78.9% at CR1, 56.6% at CR2 and 38.0% at NR respectively.
Allo-HSCT in MDS
There was no significant difference in OS rate among MDS MDS:Myelodysplastic syndrome
patients who had unrelated, sibling and haploidentical transplantation.
Patients Age of Haplo-HSCT
There was no significant difference in OS rate among MDS patients who had unrelated, sibling and haploidentical transplantation.
Result of HSCT (2018)
• Allo-HSCT Allo-HSCT:allogenic HSCT：769/773（99.5%）
• Implant success rate：768/769（99.8%）
• OS：715/769（93. 0%）
• TRM TRM:treatment related mortality of Day100：35/769（4.6%）
The first BMT in Asia in 1964 and the longest survivor:
Due to severe aplastic anemia (SAA), the patient had syn syn:syngeneic-BMT by Dr.Lu, Daopei in 1964. She is still alive and healthy until now. It is the first HSCT in Asia, also is the fourth BMT patient in the world and the longest disease-free survival in the world after BMT.
The youngest patient (2.5 months old):
The patient were born in two months due to congenital immunodeficiency disease had unrelated double umbilical cord blood transplantation in Lu Daopei hospital. The hematopoietic and immune functions had returned to normal after transplantation.
The oldest for URDURD:unrelated donor-HSCT (65 years old):
65 years old patients with ALL had hematopoietic stem cell transplantation. After the transplantation, he returned to normal life.
The heaviest (95kg) for (double) cord blood transplant:
ALL with central nervous system leukemia, the first patient who had double umbilical cord blood transplantation. After the transplantation, he was healthy and had returned to work for 14 years.